Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study

INTRODUCTION: Caplacizumab demonstrated efficacy and safety in patients with immune‐mediated thrombotic thrombocytopenic purpura (iTTP) in the phase 3 HERCULES trial. However, data on long‐term outcomes following caplacizumab treatment are limited. OBJECTIVES: The post‐HERCULES trial (NCT02878603) e...

Descripción completa

Detalles Bibliográficos
Autores principales: Scully, Marie, de la Rubia, Javier, Pavenski, Katerina, Metjian, Ara, Knöbl, Paul, Peyvandi, Flora, Cataland, Spero, Coppo, Paul, Kremer Hovinga, Johanna A., Minkue Mi Edou, Jessica, De Passos Sousa, Rui, Callewaert, Filip, Gunawardena, Sriya, Lin, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827931/
https://www.ncbi.nlm.nih.gov/pubmed/36138517
http://dx.doi.org/10.1111/jth.15892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827931/
https://www.ncbi.nlm.nih.gov/pubmed/36138517
http://dx.doi.org/10.1111/jth.15892

Ejemplares similares